This table contains 2394 series, with data for years 1991 - 1991 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (1 items: Canada ...), Population group (19 items: Entire cohort; Income adequacy quintile 1 (lowest);Income adequacy quintile 2;Income adequacy quintile 3 ...), Age (14 items: At 25 years; At 30 years; At 40 years; At 35 years ...), Sex (3 items: Both sexes; Females; Males ...), Characteristics (3 items: Life expectancy; High 95% confidence interval; life expectancy; Low 95% confidence interval; life expectancy ...).

10-year relative using US-LT and County SES-LT compared to 10-year cause specific survival for cancer patients diagnosed in the SEER-18 areas in 2000–2012 between ages 75 and 84 years both sexes combined.

BackgroundCombination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada.MethodsParticipants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.ResultsThe crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to 2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts

Abbreviation: CI, confidence interval.

Data from: Life-cycle informed restoration: engineering settlement substrate material characteristics and structural complexity for reef formation.The manuscript that has been based on these data is published in Journal of Applied EcologyThese datafiles are part of a study that defines and experimentally test the idea that life cycle-informed approaches that focus on overcoming multiple bottlenecks throughout the target species’ lifetime, instead of focusing on a single life stage, can improve restoration yields. The three experiments were conducted in the Netherlands and in Florida USA.The datasets contain data obtained from three manipulative field experiments on mussel and oyster biomass, length and individuals from the Netherlands and Florida USA.

ObjectiveNivolumab, recently proven in a phase 3 clinical trial (CheckMate 901) to enhance survival when combined with gemcitabine-cisplatin for advanced urothelial carcinoma. This study aimed to assess its cost-effectiveness against gemcitabine-cisplatin alone, from US and Chinese payers’ perspectives.MethodsA partitioned survival model was established to assess the life-years, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) of nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone as first-line treatment for advanced urothelial carcinoma. Univariate, two-way, and probabilistic sensitivity analyses were conducted to assess the model’s robustness. Additionally, subgroup analyses were performed.ResultsNivolumab plus gemcitabine-cisplatin and gemcitabine-cisplatin achieved survival benefits of 4.238 life-years and 2.979 life-years for patients with advanced urothelial carcinoma, respectively. Compared with gemcitabine-cisplatin, nivolumab plus gemcitabine-cisplatin resulted in ICERs of $116,856/QALY in the US and $51,997/QALY in China. The probabilities of achieving cost-effectiveness at the current willingness-to-pay thresholds were 77.5% in the US and 16.5% in China. Cost-effectiveness could be reached if the price of nivolumab were reduced to $920.87/100mg in China. Subgroup analyses indicated that the combination had the highest probability of cost-effectiveness in patients under 65 or with an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 in the US and China.ConclusionNivolumab plus gemcitabine-cisplatin first-line treatment for advanced urothelial carcinoma results in longer life expectancy than gemcitabine-cisplatin, but is not cost-effective in China at current price. However, cost-effectiveness is likely to be achieved in most patient subgroups in the US.

Abstract

The recovery of dead marked individuals, either alone or in combination with encounters of these individuals while alive, is an important source of data for estimating survival in birds, mammals and fish. Various models have been developed to analyse such data in a Bayesian framework, including single-state and multistate state-space models, marginalized state-space models and multinomial models. An overview of the different formulations, together with an assessment of their parameter accuracy, computational efficiency and flexibility in covariate modelling, is lacking so far. We assessed 13 models based on data simulation and analysis with the widely used R-based software NIMBLE and JAGS. We found that all the models evaluated produced accurate parameter estimates, with the exception of the multistate state-space models, which produced biased parameter estimates. This is because the standard MCMC samplers required for Bayesian inference do not work properly for this model. Although such multistate models work correctly in the frequentist framework, they should not be used in the Bayesian framework unless specially developed samplers are used. Instead, single-state state-space models, marginalized multistate state-space models, multinomial multistate models, or reparameterized multistate models should be used. The marginalized state-space and multinomial models were the most computationally efficient. The models evaluated do not differ in their ability to model temporal covariates, but do differ for individual continuous covariates. The latter can be modelled in state-space models, but not in multinomial models. We also show that single-state models can be formulated for the joint analysis of dead-recovery and live encounter data, which are usually modelled with multistate models. This facilitates the inclusion of further auxiliary data and results in a computationally efficient model. We expect our overview to help ecologists to decide which model to use when estimating survival from dead-recovery data in the Bayesian framework.

Readme

R code to reproduce the data simulation and all analyses presented in the paper. There are three files:

1. For data simulation and data analysis using NIMBLE: Code_for_NIMBLE.txt
2. For data simulation and data analysis using JAGS: Code_for_JAGS.txt
3. For producing the figures and tables presented in the paper: Results_and_figures.txt

The life expectancy for those who survive one year after a spinal cord injury depends greatly on the severity of the injury and the age of the injured. For example, a 20-year-old who survives one year after a spinal cord injury causing paraplegia can expect to live around 40.7 more years. However, if a 20-year-old survives one year after a high tetraplegia spinal cord injury, they are only expected to live about 28.7 more years on average. How many spinal cord injuries are there every year? In the United States, there are over 18,000 spinal cord injuries every year. As of 2024, there were estimated to be around 308,600 people in the United States living with a spinal cord injury. The average age when spinal injuries occur is 44 years, and vehicular accidents are the most common cause of spinal cord injuries in the United States, followed by falls and violence. Between 2015 and 2024, almost 37 percent of spinal cord injuries in the U.S. were caused by vehicular accidents, while eight percent were caused by sports accidents. The cost of spinal cord injuries Spinal cord injuries can not only impact a person’s daily living and life quality but can also have a substantial financial impact. For example, the average expenses for the first year for someone in the U.S. with a spinal cord injury causing paraplegia was 687,262 U.S. dollars as of 2024. After the first year, someone with this type of injury could expect average yearly expenses of over 91,000 U.S. dollars. All in all, the lifetime costs for a 25-year-old patient with a spinal cord injury causing paraplegia are just over three million U.S. dollars. However, a 25-year-old with a high tetraplegia spinal cord injury could expect lifetime costs of over six million U.S. dollars.

The child mortality rate in the United States, for children under the age of five, was 462.9 deaths per thousand births in 1800. This means that for every thousand babies born in 1800, over 46 percent did not make it to their fifth birthday. Over the course of the next 220 years, this number has dropped drastically, and the rate has dropped to its lowest point ever in 2020 where it is just seven deaths per thousand births. Although the child mortality rate has decreased greatly over this 220 year period, there were two occasions where it increased; in the 1870s, as a result of the fourth cholera pandemic, smallpox outbreaks, and yellow fever, and in the late 1910s, due to the Spanish Flu pandemic.

In the past four centuries, the population of the Thirteen Colonies and United States of America has grown from a recorded 350 people around the Jamestown colony in Virginia in 1610, to an estimated 346 million in 2025. While the fertility rate has now dropped well below replacement level, and the population is on track to go into a natural decline in the 2040s, projected high net immigration rates mean the population will continue growing well into the next century, crossing the 400 million mark in the 2070s. Indigenous population Early population figures for the Thirteen Colonies and United States come with certain caveats. Official records excluded the indigenous population, and they generally remained excluded until the late 1800s. In 1500, in the first decade of European colonization of the Americas, the native population living within the modern U.S. borders was believed to be around 1.9 million people. The spread of Old World diseases, such as smallpox, measles, and influenza, to biologically defenseless populations in the New World then wreaked havoc across the continent, often wiping out large portions of the population in areas that had not yet made contact with Europeans. By the time of Jamestown's founding in 1607, it is believed the native population within current U.S. borders had dropped by almost 60 percent. As the U.S. expanded, indigenous populations were largely still excluded from population figures as they were driven westward, however taxpaying Natives were included in the census from 1870 to 1890, before all were included thereafter. It should be noted that estimates for indigenous populations in the Americas vary significantly by source and time period. Migration and expansion fuels population growth The arrival of European settlers and African slaves was the key driver of population growth in North America in the 17th century. Settlers from Britain were the dominant group in the Thirteen Colonies, before settlers from elsewhere in Europe, particularly Germany and Ireland, made a large impact in the mid-19th century. By the end of the 19th century, improvements in transport technology and increasing economic opportunities saw migration to the United States increase further, particularly from southern and Eastern Europe, and in the first decade of the 1900s the number of migrants to the U.S. exceeded one million people in some years. It is also estimated that almost 400,000 African slaves were transported directly across the Atlantic to mainland North America between 1500 and 1866 (although the importation of slaves was abolished in 1808). Blacks made up a much larger share of the population before slavery's abolition. Twentieth and twenty-first century The U.S. population has grown steadily since 1900, reaching one hundred million in the 1910s, two hundred million in the 1960s, and three hundred million in 2007. Since WWII, the U.S. has established itself as the world's foremost superpower, with the world's largest economy, and most powerful military. This growth in prosperity has been accompanied by increases in living standards, particularly through medical advances, infrastructure improvements, clean water accessibility. These have all contributed to higher infant and child survival rates, as well as an increase in life expectancy (doubling from roughly 40 to 80 years in the past 150 years), which have also played a large part in population growth. As fertility rates decline and increases in life expectancy slows, migration remains the largest factor in population growth. Since the 1960s, Latin America has now become the most common origin for migrants in the U.S., while immigration rates from Asia have also increased significantly. It remains to be seen how immigration restrictions of the current administration affect long-term population projections for the United States.

In 2020, the average lifespan of a company on Standard and Poor's 500 Index was just over ** years, compared with ** years in 1965. There is a clear long-term trend of declining corporate longevity with regards to companies on the S&P 500 Index, with this expected to fall even further throughout the 2020s.